The Significance of Hurthle Cells in Thyroid Disease

被引:42
作者
Cannon, Jennifer [1 ]
机构
[1] Wake Forest Univ, Baptist Med Ctr, Dept Gen Surg, Wake Forest Univ Hlth Sci, Winston Salem, NC 27157 USA
关键词
Hurthle cell; Oncocyte; Thyroid neoplasia; Hurthle cell neoplasm; Hurthle cell carcinoma; FINE-NEEDLE-ASPIRATION; ONCOCYTIC CELL; NEOPLASMS; LESIONS; DIAGNOSIS; MALIGNANCY; MANAGEMENT; CRITERIA; BIOPSY; CANCER;
D O I
10.1634/theoncologist.2010-0253
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hurthle cells (HCs) and HC change, along with the frequently employed synonyms "oncocytes/oncocytic change" or "oxyphils/oxyphilic change," are not infrequently described on fine-needle aspiration biopsy (FNAB) reports of thyroid lesions. The description of HCs on FNAB reports may cause significant concern to the clinician; however, placing the finding in the appropriate clinical context may alleviate some anxiety. Not all oxyphilic cells are true HCs and not every aspirate containing HCs is or should be considered equivalent to an HC neoplasm (HCN). There are many benign thyroid lesions associated with HCs or HC change. For clinicians, it may be difficult to discern the significance of these findings and to determine an appropriate course of action. A skilled and experienced cytopathologist is invaluable in discriminating the subtle features that distinguish these lesions from those warranting a more aggressive approach. The diagnosis of HC carcinoma relies on histopathologic scrutiny and evidence of capsular and/or vascular invasion or metastasis to lymph nodes or distant organs. Many investigators have sought clinical, radiographic, cytological, genetic, and other factors to attempt to discriminate pre-operatively between benign and malignant HCNs. Todate, none have been definitively proven to be reliable. For now, because of the inability to determine the benign or malignant nature of such neoplasms based on cytology alone, a surgical approach is warranted. The Oncologist 2011; 16: 1380-1387
引用
收藏
页码:1380 / 1387
页数:8
相关论文
共 42 条
[1]  
Ahmed M, 2008, ANZ J SURG, V78, P139, DOI 10.1111/j.1445-2197.2007.04389.x
[2]   Fine-needle aspiration biopsy specimen with a predominance of Hurthle cells: A dilemma in the management of nodular thyroid disease [J].
Alaedeen, DI ;
Khiyami, A ;
McHenry, CR .
SURGERY, 2005, 138 (04) :650-656
[3]   Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A Synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference [J].
Baloch, Zubair W. ;
LiVolsi, Virginia A. ;
Asa, Syl L. ;
Rosai, Juan ;
Merino, Maria J. ;
Randolph, Gregory ;
Vielh, Philippe ;
DeMay, Richard M. ;
Sidawy, Mary K. ;
Frable, William J. .
DIAGNOSTIC CYTOPATHOLOGY, 2008, 36 (06) :425-437
[4]  
CARCANGIU ML, 1991, CANCER, V68, P1994
[5]   Karl Hurthle! Now, who was he? Thyroid history [J].
Caturegli, P ;
Ruggere, C .
THYROID, 2005, 15 (02) :121-123
[6]   Hurthle cell neoplasms of the thyroid - Are there factors predictive of malignancy? [J].
Chen, H ;
Nicol, TL ;
Zeiger, MA ;
Dooley, WC ;
Ladenson, PW ;
Cooper, DS ;
Ringel, M ;
Parkerson, S ;
Allo, M ;
Udelsman, R .
ANNALS OF SURGERY, 1998, 227 (04) :542-546
[7]  
Cibas ES, 2009, THYROID, V19, P1159, DOI [10.1089/thy.2009.0274, 10.1309/AJCPPHLWMI3JV4LA]
[8]   Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer [J].
Cooper, David S. ;
Doherty, Gerard M. ;
Haugen, Bryan R. ;
Kloos, Richard T. ;
Lee, Stephanie L. ;
Mandel, Susan J. ;
Mazzaferri, Ernest L. ;
McIver, Bryan ;
Pacini, Furio ;
Schlumberger, Martin ;
Sherman, Steven I. ;
Steward, David L. ;
Tuttle, R. Michael .
THYROID, 2009, 19 (11) :1167-1214
[9]   Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland - A cytomorphologic study of 139 cases with statistical analysis [J].
Elliott, DD ;
Pitman, MB ;
Bloom, L ;
Faquin, WC .
CANCER CYTOPATHOLOGY, 2006, 108 (02) :102-109
[10]   Does the fine-needle aspiration diagnosis of "Hurthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy? [J].
Giorgadze, T ;
Rossi, EP ;
Fadda, G ;
Gupta, PK ;
LiVolsi, VA ;
Baloch, Z .
DIAGNOSTIC CYTOPATHOLOGY, 2004, 31 (05) :307-312